Functional endpoints in patients with geographic atrophy: What to consider when designing a clinical trial

Further Publications

Patient-Reported Importance of Functional Benefit in Geographic Atrophy

JAMA Ophthalmol

Dinah C, Enoch J, Ghulakhszian A, Sekhon M, Salvatore S, DeSalvo G, Kumar P, Banerjee S, Nayak D, Amoaku W, Shiew M, Osoba O, Crabb DP, Taylor DJ

doi: 10.1001/jamaophthalmol.2025.3264

Further Publications

The Effect of Metagenomic Sequencing on Patient Clinical Outcomes for Intraocular Infections: A Multicenter Randomized Controlled Trial

Am J Ophthalmol

Shantha JG, Moussa K, Laovirojjanakul W, Yeh S, Tsui E, Chen JL, Vitale AT, Shakoor A, Larochelle M, Niemeyer K, Mentreddy A, Livnat I, Safo M, Ao W, Choo C, Yan D, Zhong L, Chen C, Da Silva K, Reddy AK, Lee J, Sura A, Crowell EL, Qian Y, Sharon Y, Hinterwirth A, Porco T, Arnold BF, Gonzales J, Acharya NR, Lietman TM, Doan T, OPTICS Study Group

doi: 10.1016/j.ajo.2025.07.003

Further Publications

Evaluating the Progression of Retinal Sensitivity Loss in Geographic Atrophy Using Machine-Learning-Based Structure-Function Correlation (OMEGA 2)

Invest Ophthalmol Vis Sci

Ansari G, Schärer N, Pfau K, Valmaggia P, Gabrani C, Zuche H, Giani A, Esmaeelpour M, Yamaguchi TC, Feltgen N, Maloca PM, Schmetterer L, Scholl HPN, Pfau M

doi: 10.1167/iovs.66.11.34

Macular DiseasesRetinal Diseases

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

Ophthalmology

Khanani AM, Danzig CJ, Heier JS, Jaffe GJ, Kaiser PK, Lally DR, Patel SS, Vajzovic L, Weng CY, Patel H, Clark J, Desai D, Luo D, Henry E, Holz FG, GATHER2 trial investigators

doi: 10.1016/j.ophtha.2025.12.011

Macular Diseases

Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial

Ophthalmol Ther

Brown DM, Wolf S, Veselovsky M, Veith M, Papp A, Mange S, Mondal LK, Romanczak D, Janco L, Chauhan R, Romanowska-Dixon B, Eremina A, Dusova J, Sagong M, Kim S, Bae Y, Kim S, Bae Y, Son D, Kang H, Choi S, Stanga PE

doi: 10.1007/s40123-025-01197-w

Further Publications

Proposal, Derivation, and External Validation of a Novel Geographic Atrophy Outcome Measure

JAMA Ophthalmol

Hou J, von der Emde L, Mukherjee S, Vance E, Agrón E, Domalpally A, Chew EY, Keenan TDL, AREDS2 Research Group

doi: 10.1001/jamaophthalmol.2025.6002

Macular Diseases

Long-Term Natural History of Treatment-Naïve Geographic Atrophy in Age-Related Macular Degeneration

Transl Vis Sci Technol

Muth DR, Quérat L, Venkataraman AP, Dominguez-Vicent A, Petrovski G, Williams PA, Locri F, Zweifel SA, Kvanta A

doi: 10.1167/tvst.14.5.5

Further Publications

Geographic Atrophy Multifocality in the Age-Related Eye Disease Study 2

JAMA Ophthalmol

von der Emde L, Hou J, Mukherjee S, Vance E, Agrón E, Domalpally A, Keenan TDL, AREDS2 Research Group

doi: 10.1001/jamaophthalmol.2025.3979

Blindness and Vision Impairment

Orthokeratology, 0.04% Atropine, and 0.01% Atropine for Myopia Control: A Randomized Clinical Trial

JAMA Ophthalmol

Xu H, Chen M, Ye L, Shu Q, Peng Y, Liang X, Yu T, Ji Y, Li S, Shen Q, He J, Li L, Zhu J, Xu X

doi: 10.1001/jamaophthalmol.2025.2321

Related content

Patient-Reported Importance of Functional Benefit in Geographic Atrophy

The Effect of Metagenomic Sequencing on Patient Clinical Outcomes for Intraocular Infections: A Multicenter Randomized Controlled Trial

Evaluating the Progression of Retinal Sensitivity Loss in Geographic Atrophy Using Machine-Learning-Based Structure-Function Correlation (OMEGA 2)

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial

Proposal, Derivation, and External Validation of a Novel Geographic Atrophy Outcome Measure

Long-Term Natural History of Treatment-Naïve Geographic Atrophy in Age-Related Macular Degeneration

Geographic Atrophy Multifocality in the Age-Related Eye Disease Study 2

Orthokeratology, 0.04% Atropine, and 0.01% Atropine for Myopia Control: A Randomized Clinical Trial